市场概况

The global Continuous Bioprocessing Market size is anticipated to expand from USD 133.9 百万 2022 兑美元 443.1 百万 2029, registering a compound annual growth rate (复合年增长率) 的 17.9% 在预测期内.

Continuous bioprocessing involves uninterrupted production of biopharmaceuticals using integrated systems, offering advantages such as scalability, cost savings, and consistent quality compared to traditional batch methods. It finds widespread application in the manufacturing of vaccines, 单克隆抗体, and other biologics. Market growth is driven by the rising adoption of continuous processing approaches, technological advancements, increasing investments in biomanufacturing, and supportive government initiatives and policies worldwide. 此外, the growing prevalence of chronic diseases that necessitate biopharmaceutical treatment, such as cancer, is a key factor fueling demand.

然而, stringent regulatory norms governing biopharmaceutical production and the high costs associated with continuous bioprocessing equipment and infrastructure pose challenges. The COVID-19 pandemic also disrupted research and development activities, delaying some projects in the short term.

市场细分

市场根据多种因素进行细分, including Product, 应用, End-User, and Geography

按产品细分
Filtration Systems and Consumables
Chromatography Systems and Consumables
Bioreactors
Sterilizers
Centrifuges
其他的

按应用细分
商业的
Research and Development

按最终用户细分
Pharmaceutical and Biotechnology Companies
CDMOs and CROs
Academic and Research Institutes

按地理位置细分
北美 – 美国, 加拿大, 墨西哥
欧洲 – 英国, 德国, 法国, 意大利, 西班牙, 和欧洲其他地区
亚太 – 中国, 日本, 印度, 澳大利亚, 韩国, 以及亚太地区其他地区
拉美 – 巴西, 阿根廷, 和拉丁美洲其他地区
中东和非洲 – GCC, 南非, 以及中东和非洲其他地区

The research and development segment of the continuous bioprocessing market is projected to grow significantly due to increasing R&D expenditure, growing demand for biopharmaceuticals, new facility establishments, and technological advancements. Transcenta’s breakthrough in March 2021, achieving high productivity in continuous perfusion cell culture, exemplifies the sector’s progress. Collaborative efforts, like the USP and Phlow Corp. partnership, aim to promote wider adoption of continuous manufacturing. The establishment of dedicated biomanufacturing facilities for research and development activities will further drive market growth. The research and development segment will play a crucial role in overall market expansion.

The North American continuous processing market is driven by factors such as the burden of chronic diseases, product launches, strategic initiatives by market players, facility establishments, and technological advancements. The United States is expected to hold a significant market share, driven by the demand for biopharmaceuticals. A study suggests the economic attractiveness of continuous manufacturing in the US for oral solid dosage pharmaceuticals. These factors contribute to the anticipated growth of the continuous bioprocessing market.

竞争格局

The continuous bioprocessing market is competitive, with a few major players holding significant market share. Notable companies include 3M Company, Bionet Servicios Tecnicos S.L., Bio-Rad 实验室公司, 丹纳赫公司, 多佛公司 (Colder Products Company), Eppendorf SE, Fujifilm Corporation, 洁定公司, 默克公司, Repligen Corporation, Sartorius AG, and Thermo Fisher Scientific Inc.

最新行业发展

CellulaREvolution raised GBP 1.75 million in February 2022 from notable investors, led by Happiness Capital. The funding will support their research and development efforts and strengthen their commercial team for the upcoming launch of their continuous cell culture technology.

在一月 2022, WuXi Biologics invested EUR 325 million to enhance their biomanufacturing capabilities. The investment will be used to establish a state-of-the-art facility for continuous bioprocessing, improving efficiency and productivity.

为什么购买这份报告?

Get a detailed picture of the Global Continuous Bioprocessing Market
Identify segments/areas to invest in over the forecast period in the Global Continuous Bioprocessing Market
了解竞争环境, 市场的领先参与者
Excel 格式的跨场景分析易用性的市场预估
三个月的战略咨询和研究支持
为单用户许可证提供打印验证